Search

Your search keyword '"Marie Nolla"' showing total 4 results
Start Over Author "Marie Nolla"
4 results on '"Marie Nolla"'

1. Longitudinal characterization of primary osteosarcoma and derived subcutaneous and orthotopic relapsed patient-derived xenograft models

Author

Maria Eugenia Marques da Costa, Robin Droit, Pierre Khneisser, Anne Gomez-Brouchet, Tiphaine Adam-de-Beaumais, Marie Nolla, Nicolas Signolles, Jacob Torrejon, Bérangère Lombard, Damarys Loew, Olivier Ayrault, Jean-Yves Scoazec, Birgit Geoerger, Gilles Vassal, Antonin Marchais, and Nathalie Gaspar

Subjects
osteosarcoma, patient-derived xenograft, bone, omics, RNAseq, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Abstract

Osteosarcoma is a rare bone cancer in adolescents and young adults with a dismal prognosis because of metastatic disease and chemoresistance. Despite multiple clinical trials, no improvement in outcome has occurred in decades. There is an urgent need to better understand resistant and metastatic disease and to generate in vivo models from relapsed tumors. We developed eight new patient-derived xenograft (PDX) subcutaneous and orthotopic/paratibial models derived from patients with recurrent osteosarcoma and compared the genetic and transcriptomic landscapes of the disease progression at diagnosis and relapse with the matching PDX. Whole exome sequencing showed that driver and copy-number alterations are conserved from diagnosis to relapse, with the emergence of somatic alterations of genes mostly involved in DNA repair, cell cycle checkpoints, and chromosome organization. All PDX patients conserve most of the genetic alterations identified at relapse. At the transcriptomic level, tumor cells maintain their ossification, chondrocytic, and trans-differentiation programs during progression and implantation in PDX models, as identified at the radiological and histological levels. A more complex phenotype, like the interaction with immune cells and osteoclasts or cancer testis antigen expression, seemed conserved and was hardly identifiable by histology. Despite NSG mouse immunodeficiency, four of the PDX models partially reconstructed the vascular and immune-microenvironment observed in patients, among which the macrophagic TREM2/TYROBP axis expression, recently linked to immunosuppression. Our multimodal analysis of osteosarcoma progression and PDX models is a valuable resource to understand resistance and metastatic spread mechanisms, as well as for the exploration of novel therapeutic strategies for advanced osteosarcoma.

Published
2023
Full Text
View/download PDF

2. Somatic genetic alterations predict hematological progression in GATA2 deficiency

Author

Laetitia Largeaud, Matthew Collin, Nils Monselet, Francois Vergez, Vincent Fregona, Lise Larcher, Pierre Hirsch, Nicolas Duployez, Audrey Bidet, Isabelle Luquet, Jacinta Bustamante, Stephanie Dufrechou, Nais Prade, Marie Nolla, Camille Hamelle, Suzanne Tavitian, Christophe Habib, Mateo Meynier, Christine Bellanne-Chantelot, Jean Donadieu, Flore Sicre de Fontbrune, Claire Fieschi, Alina Ferster, Francois Delhommeau, Eric Delabesse, and Marlene Pasquet

Subjects
Diseases of the blood and blood-forming organs, RC633-647.5
Abstract

Germline GATA2 mutations predispose to myeloid malignancies resulting from the progressive acquisition of additional somatic mutations. Here we describe clinical and biological features of 78 GATA2-deficient patients. Hematopoietic stem and progenitor cell phenotypic characterization revealed an exhaustion of myeloid progenitors. Somatic mutations in STAG2, ASXL1 and SETBP1 genes along with cytogenetic abnormalities (monosomy 7, trisomy 8, der(1;7)) occurred frequently in patients with GATA2 germline mutations. Patients were classified into three hematopoietic spectra based on bone marrow cytomorphology. No somatic additional mutations were detected in patients with normal bone marrow (spectrum 0), whereas clonal hematopoiesis mediated by STAG2 mutations was frequent in those with a hypocellular and/or myelodysplastic bone marrow without excess blasts (spectrum 1). Finally, SETBP1, RAS pathway and RUNX1 mutations were predominantly associated with leukemic transformation stage (spectrum 2), highlighting their implications in the transformation process. Specific somatic alterations, potentially providing distinct selective advantages to affected cells, are therefore associated with the clinical/hematological evolution of GATA2 syndrome. Our study not only suggests that somatic genetic profiling will help clinicians in their management of patients, but will also clarify the mechanism of leukemogenesis in the context of germline GATA2 mutations.

Published
2023
Full Text
View/download PDF

3. Thrombopoietin receptor agonists as an emergency treatment for severe newly diagnosed immune thrombocytopenia in children

Author

Helder Fernandes, Guy Leverger, Marlène Pasquet, Thierry Leblanc, Stéphane Ducassou, Joy Benadiba, Eric Jeziorski, Marie Nolla, Nathalie Aladjidi, Marc Michel, Corinne Pondarré, Mony Fahd, Vincent Barlogis, Pascale Blouin, CHU Toulouse [Toulouse], CIC Bordeaux, Université Bordeaux Segalen - Bordeaux 2-Institut National de la Santé et de la Recherche Médicale (INSERM), CHU Bordeaux [Bordeaux], AP-HP Hôpital universitaire Robert-Debré [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Hôpital de la Timone [CHU - APHM] (TIMONE), Hôpital Henri Mondor, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Henri Mondor-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), Centre hospitalier universitaire de Nantes (CHU Nantes), Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Pathogenesis and Control of Chronic and Emerging Infections (PCCEI), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM)-Université des Antilles (UA)-Etablissement français du don du sang [Montpellier], Centre Hospitalier Universitaire de Nice (CHU Nice), Centre Hospitalier Intercommunal de Créteil (CHIC), CHU Trousseau [APHP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Pathologies biliaires, fibrose et cancer du foie [CRSA], Centre de Recherche Saint-Antoine (CRSA), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU), Centre de Recherches en Cancérologie de Toulouse (CRCT), Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Institut Universitaire du Cancer de Toulouse - Oncopole (IUCT Oncopole - UMR 1037), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-CHU Toulouse [Toulouse]-Institut National de la Santé et de la Recherche Médicale (INSERM), Pathogénèse et contrôle des infections chroniques (PCCI), Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre Hospitalier Universitaire de Montpellier (CHU Montpellier )-Université de Montpellier (UM), Pathologies biliaires, fibrose et cancer du foie [CHU Saint-Antoine], Centre de Recherche Saint-Antoine (CR Saint-Antoine), Sorbonne Université (SU)-Institut National de la Santé et de la Recherche Médicale (INSERM)-CHU Saint-Antoine [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Sorbonne Université (SU)-Institut National de la Santé et de la Recherche Médicale (INSERM)-CHU Saint-Antoine [AP-HP], and Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)

Subjects
Male, MESH: Receptors, Thrombopoietin, Receptors, Fc, Biochemistry, Benzoates, 0302 clinical medicine, MESH: Child, Medicine, Child, ComputingMilieux_MISCELLANEOUS, MESH: Purpura, Thrombocytopenic, Idiopathic, [SDV.MHEP.HEM]Life Sciences [q-bio]/Human health and pathology/Hematology, Hematology, MESH: Thrombopoietin, MESH: Infant, 3. Good health, Hydrazines, Thrombopoietin, 030220 oncology & carcinogenesis, Child, Preschool, Female, MESH: Hydrazines, Receptors, Thrombopoietin, MESH: Receptors, Fc, MESH: Hemorrhage, Thrombopoietin Receptor Agonists, Adolescent, Recombinant Fusion Proteins, Immunology, MESH: Emergency Treatment, Hemorrhage, Newly diagnosed, Emergency treatment, 03 medical and health sciences, MESH: Recombinant Fusion Proteins, Humans, Emergency Treatment, MESH: Adolescent, Purpura, Thrombocytopenic, Idiopathic, MESH: Humans, business.industry, MESH: Child, Preschool, Infant, Cell Biology, MESH: Benzoates, Immune thrombocytopenia, MESH: Male, Pyrazoles, business, MESH: Female, MESH: Pyrazoles, 030215 immunology
Abstract

International audience

Published
2021

4. Maternal exposure to pesticides and risk of childhood lymphoma in France: A pooled analysis of the ESCALE and ESTELLE studies (SFCE)

Author

Audrey Bonaventure, Yves Bertrand, Laure Faure, Charlotte Rigaud, Jacqueline Clavel, Hélène Pacquement, Sandra Mavoungou, Laurent Orsi, Marie Nolla, Anne Lambilliotte, Mathieu Simonin, and Paula Rios

Subjects
Adult, Male, Cancer Research, medicine.medical_specialty, Adolescent, Lymphoma, Epidemiology, Population, Logistic regression, 03 medical and health sciences, 0302 clinical medicine, immune system diseases, Pregnancy, hemic and lymphatic diseases, Internal medicine, Occupational Exposure, medicine, Humans, 030212 general & internal medicine, Registries, Pesticides, education, Child, education.field_of_study, Childhood Lymphoma, business.industry, Confounding, Case-control study, Infant, Newborn, Infant, Odds ratio, medicine.disease, Oncology, Maternal Exposure, 030220 oncology & carcinogenesis, Case-Control Studies, Child, Preschool, Prenatal Exposure Delayed Effects, Female, France, business
Abstract

Background Few studies have assessed the relation between maternal prenatal pesticides use and childhood lymphoma risk, some reporting a positive association with non-Hodgkin lymphoma (NHL). We investigated the association between maternal exposure to pesticides during pregnancy and childhood Hodgkin (HL) and non-Hodgkin lymphoma. Methods We pooled data from the two French national population-based case-control studies ESCALE (2003-2004) and ESTELLE (2010-2011). Data on domestic and occupational exposures to pesticides during pregnancy were obtained through standardised maternal interviews. Logistic regression models were used to compute odds ratios (OR) and 95% confidence intervals (CI) for HL and NHL, by pesticide category adjusted for potential confounders. Analyses by histological subtypes were also performed. Results We included 328 H L, 305 non-Hodgkin NHL and 2,415 controls. Around 40% of control mothers reported having used pesticides during index pregnancy, of whom 95% reported insecticides use. Maternal use of herbicides and fungicides occurred mostly in combination with insecticides. Insecticides use was more frequently reported in cases than controls (ORNHL = 1.6 [95%CI 1.3–2.1], p = 0.0001; ORHL = 1.3 [95%CI 1.0–1.7], p = 0.03). This association appeared more marked for Burkitt lymphoma and mixed cellularity classical HL. No obvious association was observed with occupational pesticides exposure during pregnancy. Conclusion These results suggest that maternal domestic use of insecticides during pregnancy might be related to both childhood NHL and HL. Further larger studies are urgently needed.

Published
2020

Catalog

Books, media, physical & digital resources
See catalog results